Across these datasets, we identified 12 potential mutations associated with FGFR3 activation, including notable variants R248C, S249C, Y373C, and G380R, which are most prevalent in bladder cancer but occur infrequently in breast cancer (Supplemental Figure 2A). This evidence concerns the gene FGFR3 and breast carcinoma.